{
    "clinical_study": {
        "@rank": "159676", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 - Progesterone Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4."
            }, 
            {
                "arm_group_label": "Arm 2 - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm)  for 4 weeks beginning on postpartum day 4."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary goal of this project is to investigate the potential efficacy of exogenous\n      progesterone (with supplemental relapse prevention counseling) on postpartum relapse in new\n      mothers.  Also to determine the feasibility of enhanced compliance monitoring and\n      identification of collateral factors effecting outcomes."
        }, 
        "brief_title": "Progesterone & Postpartum Relapse to Smoking", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Tobacco Use Cessation", 
            "Tobacco Use Disorder"
        ], 
        "condition_browse": {
            "mesh_term": "Tobacco Use Disorder"
        }, 
        "detailed_description": {
            "textblock": "Pregnant women will be recruited at gestational weeks 33-36 who have quit smoking during\n      pregnancy and are motivated to maintain abstinence after delivery.  At the time of delivery,\n      women will be randomly assigned to receive 4 weeks of active or placebo exogenous\n      progesterone starting on the 4th day postpartum.  Participants will be in contact with study\n      staff either by phone or clinic visits until 12 weeks postpartum to collect data on smoking\n      status and protocol compliance, measure serum progesterone levels and receive behavioral\n      counseling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pregnant women at 33-36 weeks gestation who have quit smoking during pregnancy\n\n          -  Confirmed uncomplicated single-gestation pregnancy\n\n          -  Established prenatal care\n\n          -  English fluency\n\n          -  Ability to provide informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798394", 
            "org_study_id": "2012NTLS059", 
            "secondary_id": "R21DA034840"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1 - Progesterone Group", 
                "intervention_name": "Progesterone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2 - Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Progesterone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pregnant", 
            "smoker", 
            "cigarette", 
            "tobacco"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "tosun004@umn.edu", 
                "last_name": "Nicole L. Tosun, M.S.", 
                "phone": "612-624-5350"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55414"
                }, 
                "name": "University of Minnesota, 717 Delaware Street SE"
            }, 
            "investigator": {
                "last_name": "Sharon S. Allen, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Progesterone & Postpartum Relapse to Smoking", 
        "overall_contact": {
            "email": "tosun004@umn.edu", 
            "last_name": "Nicole L Tosun, M.S.", 
            "phone": "612-624-5350"
        }, 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Sharon S. Allen, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determined by seven-day point prevalence, a binary smoking relapse outcome - defined as a single puff of a cigarette during the seven days prior to a pre-specified time point of interest.", 
            "measure": "Relapse Rate", 
            "safety_issue": "No", 
            "time_frame": "Week 4 Postpartum"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798394"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determined by seven-day point prevalence, a binary smoking relapse outcome - defined as a single puff of a cigarette during the seven days prior to a pre-specified time point of interest.", 
                "measure": "Relapse Rate", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Defined by continuous abstinence (CA) and prolonged abstinence (PA). CA defined as a single puff of a cigarette as a relapse. PA measure reflects sustained abstinence and defines relapse as seven consecutive slip (e.g., a puff or more) without a 24 hours period between any slip.", 
                "measure": "Days to Relapse", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 84"
            }, 
            {
                "description": "Defined as the complete requirements (e.g.,number of visits attended, doses of medication taken, electronic data capture completed) divided by number possible multiplied by 100%.", 
                "measure": "Protocol Compliance", 
                "safety_issue": "No", 
                "time_frame": "Gestational Week 35 and Weeks 2, 6, and 12 Postpartum"
            }, 
            {
                "description": "This is a questionnaire assessing participant expectations, satisfaction and study protocol, study medication and electronic data capture. It contains 10 scaled items adapted from a published instrument; all questions are answered with a four-point Likert-type scale. The score of the feasibility questionnaire will be determined by computing a sum, yielding an acceptability score.", 
                "measure": "Compliance Determinants", 
                "safety_issue": "No", 
                "time_frame": "Gestational Week 36 and Weeks 2, 6 and 12 Postpartum"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Institute on Drug Abuse (NIDA)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}